B‑Vitamin Supplementation to Prevent Levodopa‑Induced Hyperhomocysteinemia in Parkinson’s Disease

Rationale and Need for Supplementation

Levodopa metabolism via catechol‑O‑methyltransferase depletes vitamin B6, vitamin B12, and folate, leading to systemic B‑vitamin deficiency that worsens as levodopa dose increases. 1
Even low daily levodopa doses (≈250 mg) produce measurable B‑vitamin depletion; higher levodopa doses require proportionally greater B‑vitamin intake to maintain normal homocysteine concentrations. 1
Hyperhomocysteinemia reliably develops in patients receiving levodopa, with plasma homocysteine rising in direct proportion to levodopa dose and inversely to B‑vitamin status. 1

The recommended folic acid component of a B‑vitamin complex is 0.4 mg – 5 mg per day; 0.4 mg corresponds to the Recommended Dietary Allowance, while doses up to 5 mg are reserved for cases where homocysteine remains elevated despite standard supplementation. [2][3]
The maximal vascular benefit of folic acid is achieved at the RDA level (0.4 mg/day); increasing the dose to 5 mg/day does not further improve vascular function, although plasma 5‑MTHF rises proportionally with dose. [2][3]

All patients initiating levodopa‑carbidopa therapy should receive a combined B‑vitamin complex (vitamin B6, vitamin B12, and folate) rather than isolated L‑5‑MTHF or single‑vitamin products, because levodopa depletes all three simultaneously. 1
Patients on higher daily levodopa doses should be given the upper end of the folic acid range (up to 5 mg/day) and may require increased amounts of vitamin B6 and vitamin B12 to keep homocysteine within the normal range. 1

Plasma homocysteine should be measured regularly, especially when levodopa doses are escalated, because concentrations correlate positively with levodopa dose, older age, and longer disease duration, and inversely with B‑vitamin status. 1
Ongoing assessment of vitamin B6, vitamin B12, and folate levels is recommended for all patients on levodopa‑carbidopa to ensure adequacy of supplementation. 1

Do not wait for documented hyperhomocysteinemia before starting B‑vitamin supplementation; prophylactic supplementation should begin at levodopa initiation because depletion occurs even at low doses. 1
Do not rely on over‑the‑counter multivitamins as a substitute for a therapeutic B‑vitamin complex, since many such products do not contain sufficient B‑vitamin amounts to counteract levodopa‑induced depletion, particularly in patients on high levodopa doses. 1

Levodopa metabolism via catechol‑O‑methyltransferase (COMT) consumes vitamin B6, vitamin B12, and folate as essential cofactors, leading to their systemic depletion. 4
Carbidopa irreversibly binds pyridoxal‑5′‑phosphate, the active form of vitamin B6, further reducing available B6 stores. 4
Even low daily levodopa doses (≈250 mg) cause measurable B‑vitamin depletion; higher levodopa doses require proportionally greater B‑vitamin intake to maintain balance. 4

Hyperhomocysteinemia reliably develops in levodopa‑treated Parkinson’s patients, with plasma homocysteine levels rising in direct proportion to levodopa dose and inversely to B‑vitamin status. 4
Combined supplementation with vitamin B6, vitamin B12, and folate effectively lowers homocysteine concentrations and prevents levodopa‑associated peripheral neuropathy. 4

The 2026 Praxis Medical Insights guideline issues a strong recommendation (high‑quality evidence) for universal B‑vitamin complex supplementation in all Parkinson’s patients receiving levodopa‑carbidopa. 4
The 2018 ESPEN neurology guidelines also endorse routine B‑vitamin supplementation for Parkinson’s disease patients on levodopa, providing moderate‑strength evidence. 5

A standard B‑vitamin complex (containing B6, B12, and folate) is the preferred formulation rather than administering the vitamins individually. 4
Routine monitoring of plasma homocysteine is advisable, especially when levodopa doses are escalated, to ensure adequacy of B‑vitamin supplementation. 4

Parkinson’s patients typically exhibit lower serum vitamin D concentrations than age‑matched peers; supplementation may decelerate disease progression and reduce fracture risk by preserving bone‑mineral density. 4